Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1991-11-05
1994-01-04
Rose, Shep K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
424449, 514171, A61K 3156, A61K 31565, A61K 3157, A61K 3158
Patent
active
052760227
ABSTRACT:
This invention is concerned with a contraceptive formulation and a method of contraception which employs a combination of estrogen and progestin and wherein a short period of relatively dominant estrogenic activity alternates with a short period of relatively dominant progestagenic activity. The invention also concerns a hormonal replacement formulation and method for use in menopausal or castrate women which employs a similar combination of estrogen and progestin.
REFERENCES:
patent: 3409721 (1968-11-01), Applezweig
patent: 3502772 (1970-03-01), Ijzerman
patent: 3568828 (1971-03-01), Lerner
patent: 3795734 (1974-03-01), Rochefort
patent: 3822355 (1974-07-01), Kincl
patent: 3836651 (1974-09-01), Rudel et al.
patent: 3924641 (1976-03-01), Segre
patent: 3932635 (1976-01-01), Segre
patent: 3939264 (1976-02-01), Lachnit-Fixson
patent: 3957982 (1976-05-01), Lachnit-Fixson et al.
patent: 3969502 (1976-07-01), Lachnit-Fixson
patent: 4076811 (1978-02-01), Lachnit-Fixson et al.
patent: 4143136 (1979-03-01), De Jage et al.
patent: 4145416 (1979-03-01), Lachnit-Fixson et al.
patent: 4291028 (1981-09-01), Vorys
patent: 4292315 (1981-09-01), Vorys
patent: 4378356 (1983-03-01), De Jager
patent: 4390531 (1983-06-01), Edgren
patent: 4425339 (1984-01-01), Pitchford
patent: 4530839 (1985-07-01), Pasquale
patent: 4544554 (1085-10-01), Pasquale
patent: 4616006 (1986-10-01), Pasquale
patent: 4621079 (1986-11-01), Lachnit-Fixson et al.
patent: 4624665 (1986-11-01), Nuwayser
patent: 4628051 (1986-12-01), Pasquale
patent: 4687481 (1987-08-01), Nuwayser
patent: 4810499 (1989-03-01), Nuwayser
patent: 4816258 (1989-03-01), Nedberge et al.
patent: 4818540 (1989-04-01), Chien et al.
patent: 4826831 (1989-05-01), Plunkett et al.
patent: 4834978 (1989-05-01), Nuwayser
patent: 4906169 (1990-03-01), Chien et al.
patent: 4927687 (1990-05-01), Nuwayser
patent: 4962098 (1990-10-01), Boissonneault
patent: 4994449 (1991-02-01), Leonard
patent: 5023084 (1991-06-01), Chien et al.
patent: 5108995 (1992-04-01), Casper
patent: 5122382 (1992-06-01), Gale et al.
Unlisted Drugs, vol. 38, No. 1, Jan. 1986, p. 2, Ref. 0.
Rote Liste, 1987, Entry No. 75154 "Perkiursal".
Rote Liste, 1987, Entry No. 75156 "Sinovula".
Rote Liste, 1987, Entry No. 75157 "Synphasic".
Tseng et al., "Effects of Progestins on Estradiol Receptor Levels in human Endometrium", J. Clin. Endocrinol. Metabl., vol. 41, pp. 402-407 (1975).
Bayard et al., "Cytoplasmic and Nuclear Estradiol and Progesterone Receptors in Human Endometrium" J. of Clin. Endocrinology and Metabolism, vol. 46, No. 4, pp. 635-648 (1978).
Kreitmann et al. "Estrogen and Progestin Regulation of the Progesterone Receptor Concentration in Human Endometrium", J. of Clin. Endocrinology and Metabolism, vol. 49, No. 6, pp. 926-929 (1979).
Walters et al., "Relationship between the Quality of Progesterone Receptor and The Antgonism of Estrogen-Induced Uterotropic Response", Endocrinolgy, vol. 105, No. 2, pp. 382-386 (1979).
Kreitmann-Gimbal et al., "Patterns of Estrogen and Progesterone Receptors in Monkey Endometrium During the Normal Menstrual Cycle", Steriods, vol. 35, No. 4, pp. 471-479 (1980).
Alexandrova et al., "Oxytocin Receptors and Parturition in the Guinea Pig", Biology of Reproduction, vol. 22, pp. 1106-1111 (1980).
Katzenellenbogen, "Dynamics of Steroid Hormone Receptor Action", Ann. Rev. Physiol., vol. 42, pp. 17-35 (1980).
Whitehead et al., "Effects of Estrogens and Progestins on the Biochemistry and Morphology of the Postmenopausal Endometrium", New Engl. J. Med., vol. 305, No. 27, pp. 1599-1605 (1981).
Eckert et al., "Human Endometrial Cells in Primary Tissue Culture: Modulation of the Progesterone Receptor Level . . . ", J. of Clin. Endocrinology and Metabolism, vol. 52, No. 4, pp. 699-708 (1981).
West et al., "Progesterone-Mediated Suppression of Estradiol Receptors in Cynomolgus Macaque Cervix Endometrium and Oviduct . . . ", J. Steriod Biochem., vol. 22, No. 1, pp. 29-37 (1985).
Leavitt et al., "Rapid Recovery of Nuclear Estrogen Receptor and Oxytocin Receptor in the Ovine Uterus following Progesterone Withdrawal", J. Steriod Biochem., vol. 22, No. 6, pp. 687-691 (1985).
Neumannova et al., "Short-Term Effects of Tamoxifen, Medroxyprogesterone Acetate, and Their combination on Receptor . . . ", Obstetrics & Gynecology, vol. 66, No. 5, pp. 695-700 (1985).
Jensen et al., "Continuous Oestrogen-Progestogen Treatment and Serum Lipoproteins in Postmenopausal Women", Brit. J. of Obstetrics and Gynaecology, vol. 94, pp. 130-135 (1987).
"Cyclo-Progynova" Unlisted Drugs, 22:(10) 160 (1973).
"Microgynon" Unlisted Drugs, 25:(10) 160 (1973).
"WL-20" Unlisted Drugs, 26:(11) 170 (1974).
"Minidrial" Unlisted Drugs, 28:(2) 26 (1976).
Chemical Abstracts, 83:72528q (1975).
Hirvonen et al., "Effects of Different Progesterones on Lipoproteins During Postmenopausal Replacement Therapy", New Eng. J. Med., 304:560-563 (1981).
Jencap Research Ltd.
Rose Shep K.
LandOfFree
Hormone preparation and method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hormone preparation and method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hormone preparation and method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-307218